A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

101

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions

Gastric CancerColorectal Cancer

Interventions

DRUG

SHR-A1811

There are six pre-defined dose regimens . Subjects will be enrolled with an initial dose

Trial Locations (1)

Shanghai East Hospital, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY